Skip to content
Screener

MaxCyte MXCT Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$8.5MMiss by $1.9M
EPS-$0.12Miss by $0.02
Revenue estimate$10.4M
EPS estimate-$0.10

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$7.0M
EPS estimate-$0.08

Financials

Q2 2025

Income statement

See full
Revenue$8.5M-18.4%
Gross profit$7.0M-21.8%
Operating income-$14.2M-18.9%
Net income-$12.4M-31.8%
EPS (diluted)-$0.12-33.3%

Balance sheet

See full
Cash & equivalents$15.2M-59.4%
Total debt$18.5M-0.1%
Total equity$190.7M-13.8%
Total assets$219.8M-12.6%

Cash flow

See full
Operating cash flow-$9.9M-104%
CapEx$584.0K+98.6%
Free cash flow-$10.4M-104%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$235.5M-42.3%
Enterprise value$238.78M-38.6%
P/S6.6×-2.4×

Profitability

See full
Gross margin79.8%-8.6pp
Operating margin-149.6%+132pp
Net margin-125.2%+193pp
FCF margin-107%+1,090pp

Returns & leverage

See full
Return on equity-21.7%+15.6pp
Debt / equity0.1×0.0×
Current ratio12.4×-1.9×

Segments

By product

See full
License$2.9M-46.4%
Assay And Other Service Revenue$310.0K+35.4%

By segment

See full
Cell Engineering Technology$8.5M-18.4%

By geography

See full
US$5.3M—

FAQ

When did MaxCyte report Q2 2025 earnings?
MaxCyte (MXCT) reported Q2 2025 earnings on August 6, 2025 after market close.
What were MaxCyte's Q2 2025 revenue and EPS?
MaxCyte reported revenue of $8.5M and eps of $-0.12 for Q2 2025.
Did MaxCyte beat estimates in Q2 2025?
Revenue missed the consensus estimate of $10.4M by $1.9M. EPS missed the consensus estimate of $-0.10 by $0.02.
How did MaxCyte's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 18.4% from $10.4M a year earlier and eps declined 33.3% from $-0.09.
Where can I find MaxCyte's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-010523) and the 10-Q periodic report (0001558370-25-010554) directly on SEC EDGAR. The filing index links above go to sec.gov.